Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus LIQUID PRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus LIQUID PRED.
ARISTOCORT vs LIQUID PRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
5-60 mg/day orally in divided doses; typical starting dose 5-10 mg every 6-12 hours.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
2.1–3.5 hours (terminal elimination half-life; shorter half-life in children; prolonged in hepatic impairment).
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Primarily renal: prednisolone is excreted as glucuronide and sulfate conjugates; less than 1% unchanged. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid